| cbdMD (NYSE American: YCBD) Investor Webinar Replay Now Available |
| |
|
RedChip hosted an exclusive investor webinar with cbdMD (NYSE American: YCBD) last week.
During the presentation, Marty Sumichrast, Chairman and co-CEO of cbdMD, outlined the company’s growing product portfolio, including its newly revamped CBD pet line, and expanding retail distribution in the high-growth CBD space.
Watch the replay now: youtu.be/YHZ1rzDZ_1I
Recently named “Brand to Watch” by leading industry researchers at Brightfield Group, cbdMD’s innovative marketing approach has helped the brand reach millions of potential customers.
In addition to being the first CBD company listed on the NYSE American, cbdMD is the official founder of National CBD Day (August 8) and National Hemp Day (February 4).
In April, cbdMD became the first CBD company to sponsor a major professional sports league, the BIG3, and has maintained its recurring partnership with Nitro Circus. Team cbdMD is made up of Bubba Watson, Lolo Jones, Kerri Walsh Jennings, Chad Reed, Quinton "Rampage" Jackson, Ryan Sheckler, Tyron Woodley, Michael Bisping, Vicki Golden, Ken Block, and more.
"There is a massive shakeup in the CBD industry with smart, savvy companies effectively leveraging marketing and PR to disrupt the previous leaders," said Bethany Gomez, Brightfield Group's Managing Director. "cbdMD has leveraged high profile sponsorships better than anyone to rapidly gain a massive consumer base and break into the top 20 CBD companies in the country."
Disclosure
cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.
|
|
| |
|
| GSRX Industries (OTCQB: GSRX) Announces Plans for Second Dispensary in California |
| |
|
GSRX Industries (OTCQB: GSRX) announced that it has retained celebrated architects Studio AR&D and Leap Interior Design for the creation of the Company’s newest The Green Room adult-use and medicinal cannabis dispensary in Palm Springs. The Company currently owns and operates The Green Room in Point Arena, California, as well as five Green Spirit RX medicinal cannabis dispensaries in Puerto Rico, with more slated to open there soon.
Why It Matters: GSRX’s newest The Green Room will be located in a free-standing 4,500 square foot building that includes a private patio area and ample customer parking. The site is considered a prime retail location, where CA Highway 111 becomes N. Palm Canyon Drive, the main entrance to the City of Palm Springs from I-10 and Los Angeles. Plans call for the building to be completely redesigned from the ground up, in a contemporary update on the classic mid-century modern style which thrived in Palm Springs architecture and design from the 1930s to the mid-1960s.
Key Quote: "Inspired by the storied history of this building, where Frank Sinatra and his Rat Pack pals regularly held court in Booth #6, we are honoring the cool style of that era with an updated flair, and given its reinvention as a cannabis dispensary, we are creating the kind of hip space that could easily become the new ‘relaxation destination’ for modern day Rat Packers.” – Sean Lockyer, President, Studio AR&D Architects
Background: Studio AR&D’s work has been featured in publications including the New York Times, Dwell, Desert, Wallpaper, the Los Angeles Times, Palm Springs Life, and others.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| Immuron (NASDAQ: IMRN) to Host Group Call on August 1 |
| |
|
Immuron (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, will host a group call with investors this Thursday, August 1, at 2 pm ET.
Immuron’s technology platform utilizes highly specific vaccines for the generation of hyperimmune antibody-rich bovine colostrum, providing a means of antimicrobial therapy without the drawbacks of antibiotics to treat gut-mediated diseases.
The Company currently markets Travelan®, which is a listed medicine on the Australian Register for Therapeutic Goods, in Australia to reduce the risk of travelers’ diarrhea. In Canada, Travelan® is a licenced natural health product, and is indicated to reduce the risk of travelers’ diarrhea. In the U.S. Travelan® is sold as a dietary supplement for digestive tract protection.
The Company recently announced plans to pursue clinical development of IMM-124E through a formal FDA registration pathway as a drug to specifically prevent travelers’ diarrhea.
Immuron’s IMM-124E is also presently in Phase II trials in severe alcoholic hepatitis (ASH), and pediatric non-alcoholic fatty liver disease (NAFLD), respectively.
Immuron’s second clinical-stage asset, IMM-529, targets Clostridium difficile infections (CDI), and is presently in a clinical trial in CDI patients. The Company plans to file an IND with FDA to focus its further development specifically to treat patients with recurrent CDI.
To participate in this week’s group call, please reach Craig Brelsford, RedChip Specialist, at (407) 571-0902, or write to craig@redchip.com. Craig will send you the dial-in info.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Provides Shareholder Update on Key Initiatives |
| |
|
In its latest shareholder update, SinglePoint (OTCQB: SING) announces its Direct Solar subsidiary just achieved its largest weekend in contracts closed to date. Direct Solar is fundamentally changing SinglePoint’s underlying structure and building a solid financial base for the company to continue growth and acquisitions. Direct Solar has exceeded expectations, growing quickly and providing opportunities such as commercial solar applications and renewable energy financing options.
Why It Matters: Direct Solar enables residential solar customers to shop their options in order to find the best option for the home. Similar to Rocket Mortgage or Lending Tree, Direct Solar representatives are able to provide homeowners with a variety of financing and service providers. This has made the process of buying solar much easier for homeowners which has led to a quick increase in the company’s overall growth. After only 60 days the company has contracted more than $3,000,000 in residential solar contracts.
Key Quote: “The traction we have experienced so far has been amazing. We are thrilled for the achievements we have accomplished and are looking forward to continually improving. We are now exploring ways to generate additional sales through innovative marketing strategies. I’m confident we will hit $15,000,000 in 2020.” – Pablo Diaz, CEO of Direct Solar
What’s Next: Expanding their reach, Direct Solar has attracted the attention of lenders interested in financing renewable energy applications. Previously there were few options for lending to commercial operations in this space. For a lender to find a project, vet the opportunity, and make a decision to fund or not, is a long and labor-intensive process. Direct Solar provides a unique solution for lenders, building owners, and management. For lenders, Direct Solar is providing vetted projects with vetted services providers. Lenders simply provide Direct Solar their list of requirements in order to fund a project and receive only those fitting within that scope. For commercial customers, Direct Solar provides a one-stop shop in which businesses can apply for and receive financing for their project once approved.
Disclosure
SinglePoint, Inc. (OTCQB: SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services
|
|
| |
|
| Catasys (NASDAQ: CATS) Launches Breakthrough AI Capability to Address Chronic Disease |
| |
|
Catasys (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, announced Catasys PRETM (Predict-Recommend-Engage).
Catasys has long been recognized as the leader in utilizing a sophisticated algorithm to identify care avoidant members who have untreated behavioral health conditions. Now, Catasys is launching an evolved model—Catasys PRE—which applies the Company’s capabilities beyond behavioral health conditions to chronic conditions including, as examples, cardiovascular disease, diabetes, and pulmonary disease.
Key Quote: “Using the latest techniques in AI and over a decade of research, Catasys has solved these challenges by creating what we believe to be the most valuable technology platform for populations that are care avoidant or not engaging in care. We can now predictively and rapidly identify care avoidant individuals with major chronic disease and those for whom targeted interventions will improve outcomes and reduce the cost of care.” – Keith Phillips, President & CEO
The Backstory: Catasys harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and validated outcomes and savings to health plans. Our mission is to help improve the health and save the lives of as many people as possible.
Catasys' integrated, technology-enabled OnTrak solution--contracted with a growing number of national and regional health plans--is designed to treat members with behavioral conditions that cause or exacerbate co-existing medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure, which result in high medical costs.
Catasys has a unique ability to engage these members, who do not otherwise seek behavioral healthcare, leveraging proprietary enrollment capabilities built on deep insights into the drivers of care avoidance.
OnTrak integrates evidence-based psychosocial and medical interventions delivered either in-person or via telehealth, along with care coaching and in-market Community Care Coordinators who address the social determinants of health, including loneliness. The program improves member health and delivers validated cost savings to healthcare payers of more than 50 percent for enrolled members. OnTrak is available to members of several leading health plans in Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Mississippi, Missouri, Nebraska, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.
Disclosure
Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Interpace (NASDAQ: IDXG) Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR® |
| |
|
Interpace Diagnostics Group (NASDAQ: IDXG) announced that it has entered into a contract with Blue Shield of California, a not-for-profit independent member of the Blue Cross Blue Shield Association making ThyGeNEXT and ThyraMIR tests in-network services for their 4 million lives. Blue Shield originally granted coverage for ThyGeNEXT and ThyraMIR in March of 2018. Now, members will be able to access Interpace’s molecular thyroid tests on an in-network basis, which will limit their out of pocket expenses and optimize their benefits in accordance with their in-network benefit levels.
Why It Matters: According to Jack Stover, CEO of Interpace, “Adding Blue Shield of California under contract and as an in-network provider is beneficial to both the Blue Shield of California members as well as Interpace and represents another milestone in solidifying our molecular thyroid products’ place in the market.”
The Backstory: Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace’s Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX® that differentiates lung cancer of primary vs. metastatic origin.
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) Wins 2019 Golden Eagle Award for its Technology Deployed at MetLife Stadium |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced digital technology products for law enforcement, homeland security and commercial security applications, was the 2019 Golden Eagle Award winner at the National Sports Safety and Security Conference & Exhibition, in New Orleans, Louisiana. The award recognizes outstanding security projects executed in sporting venues.
Key Quote: "Our technology deployment at MetLife Stadium in 2018 was designed to meet the security team’s goal of improving accountability and transparency for security, reducing civil liability, and having a tool to help de-escalate volatile situations,” commented Stanton E. Ross, CEO of Digital Ally” – Les Ball, CEO
The Backstory: Digital Ally®, headquartered in Lenexa, KS, specializes in the design and manufacture of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, commercial fleets, and consumer use. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"Don't put too much money in any one stock, spread it out, you never know which ones will be your big winner."
- Buzz Heidkte, Owner MidSouth Investor Fund |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
